Johnson & Johnson presented new Phase 3 and real-world data for IMAAVY® (nipocalimab-aahu) at EAN 2026, showing earlier treatment improves outcomes in generalized myasthenia gravis and reinforcing safety across diverse patient populations.
Written By: Kirti Kumbhar, M. Pharm (QA)
Reviewed By: Pharmacally Editorial Team
Johnson & Johnson has presented new clinical data for IMAAVY® (nipocalimab-aahu) at the European Academy of Neurology (EAN) 2026 Congress, providing additional evidence that early treatment may improve outcomes for patients with generalized myasthenia gravis (gMG). The company reported findings from 12 abstracts, including post hoc analyses of the pivotal Phase 3 Vivacity-MG3 trial (NCT04951622) and ongoing real-world research addressing important clinical questions such as pregnancy and infection management.
Scientific and Clinical Context
Generalized myasthenia gravis is a chronic autoimmune neuromuscular disorder in which pathogenic immunoglobulin G (IgG) autoantibodies, most commonly against the acetylcholine receptor (AChR) or muscle-specific kinase (MuSK), disrupt communication between nerves and muscles. The resulting muscle weakness can impair vision, speech, swallowing, breathing, and mobility.
IMAAVY is a neonatal Fc receptor (FcRn) blocker that selectively reduces circulating pathogenic IgG antibodies while preserving key components of humoral immune function. The therapy is currently approved in the United States and Europe for adults and adolescents aged 12 years and older with anti-AChR- or anti-MuSK-positive gMG.
Phase 3 Data Highlight Benefits of Earlier Treatment
New post hoc analyses from Vivacity-MG3 showed that patients treated within five years of diagnosis achieved greater improvements in daily functioning than those receiving placebo plus standard of care. At Week 24, patients receiving IMAAVY experienced a mean reduction of 4.9 points in MG-ADL scores, compared with 2.7 points in the placebo group (p=0.005). More patients also achieved sustained meaningful clinical improvement lasting at least 20 weeks.
Among patients with lower baseline disease burden (MG-ADL score below 9), IMAAVY again produced superior clinical outcomes. MG-ADL scores improved by 4.5 points versus 2.3 points with placebo, while Quantitative Myasthenia Gravis (QMG) scores also showed significantly greater reductions (p<0.001 for MG-ADL and p=0.001 for QMG). These findings suggest that earlier intervention may maintain disease control before symptoms become more severe.
Investigators also reported that patients receiving IMAAVY generally maintained symptom control following common infections, which frequently trigger disease exacerbations in gMG. Safety remained consistent with previous studies. Adverse events occurred at similar rates across treatment and placebo arms (84%), while serious adverse events were reported in 9% of IMAAVY-treated patients compared with 14% in the placebo arm. Because the therapy may increase infection risk, treatment should be delayed in patients with active infections until they recover.
Expanding the Evidence Base
Neurologist Carlo Antozzi, M.D. said the new analyses strengthen evidence supporting sustained disease control across different stages of generalized myasthenia gravis, including patients earlier in their disease course. Johnson & Johnson’s Global Immunology Therapeutic Area Head David Lee, M.D., Ph.D. added that the company continues to investigate IMAAVY across multiple autoantibody-mediated diseases while evaluating its potential to provide durable disease control throughout patients’ lives.
Regulatory Path Forward
Johnson & Johnson also highlighted the PETUNIA post-marketing study, an FDA-required registry that will collect prospective and retrospective real-world data on pregnancy, maternal health, and infant outcomes following IMAAVY exposure during pregnancy. The initiative aims to address a major evidence gap for women of child-bearing potential living with gMG and support future clinical decision-making. Alongside ongoing long-term extension studies, these data will further define IMAAVY’s role across the evolving treatment landscape for generalized myasthenia gravis.
Reference
About the Writer
Kirti Kumbhar (LinkedIn) is an M.Pharm graduate with experience in Quality Assurance at Lupin Limited and a strong interest in clinical research, regulatory affairs, and Trial Master File (TMF) management. She has developed knowledge of regulatory documentation, quality systems, compliance, and healthcare research through her professional experience. Passionate about clinical development and continuous learning, Kirti is committed to supporting high-quality healthcare documentation, regulatory excellence, and research-driven healthcare advancements.